No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CGEM240517P22500
- 0.38
- -0.42-52.50%
15min DelayTrading May 9 09:30 ET
0.38High0.01Low
0.01Open0.80Pre Close5 Volume63 Open Interest22.50Strike Price127.00Turnover122.16%IV-19.03%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.38Time Value100Contract SizeAmericanOptions Type-0.1371Delta0.0437Gamma71.89Leverage Ratio-0.0648Theta-0.0009Rho-9.86Eff Leverage0.0090Vega
Intraday
- 5D
- 1D
News
Cullinan Therapeutics Insider Sold Shares Worth $1,796,676, According to a Recent SEC Filing
Jennifer Michaelson, Chief Scientific Officer, on May 06, 2024, sold 63,606 shares in Cullinan Therapeutics (CGEM) for $1,796,676. Following the Form 4 filing with the SEC, Michaelson has control over
Insider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ...
Cullinan Therapeutics(CGEM.US) Officer Sells US$1.8 Million in Common Stock
$Cullinan Therapeutics(CGEM.US)$ Officer Michaelson Jennifer sold 63,606 shares of common stock on May 6, 7, 2024 at an average price of $28.25 for a total value of $1.8 million.Source: Announcement W
Investor Sentiment Swings in Favor of Cullinan Therapeutics (NASDAQ:CGEM)
Express News | Cullinan Therapeutics Inc : Stifel Initiates Coverage With Buy Rating; Target Price $40
Cullinan Oncology Initiated at Buy by Stifel
Cullinan Oncology Initiated at Buy by Stifel
Comments
$Cullinan Therapeutics(CGEM.US$
NEWS
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
NEWS
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
Gainers:
• $Cullinan Therapeutics(CGEM.US$ +22.4% (Cullinan Management and Taiho Pharmaceutical to collaborate to jointly develop and commercialize CLN081/TAS6417 and Taiho's acquisition of Cullinan Pearl)
• $Lordstown Motors(RIDE.US$ +17.2% (closes asset purchase agreement with Foxconn)
• $Applovin(APP.US$ +15.5%(In reaction to earnings)
• $SmartRent(SMRT.US$ +15.4%(In reaction to earnings)
• $Coupang(CPNG.US$ +14.3%(In reaction to earn...
• $Cullinan Therapeutics(CGEM.US$ +22.4% (Cullinan Management and Taiho Pharmaceutical to collaborate to jointly develop and commercialize CLN081/TAS6417 and Taiho's acquisition of Cullinan Pearl)
• $Lordstown Motors(RIDE.US$ +17.2% (closes asset purchase agreement with Foxconn)
• $Applovin(APP.US$ +15.5%(In reaction to earnings)
• $SmartRent(SMRT.US$ +15.4%(In reaction to earnings)
• $Coupang(CPNG.US$ +14.3%(In reaction to earn...
12
3
Read more